Publications

Leukemia. 2014 May 14. [Epub ahead of print] A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Bae J, Prabhala R, Voskertchian A, Brown A, Maguire C, Richardson P, Dranoff G, Anderson KC, Munshi NC.

Clin Cancer Res. 2012 Sep 1; 18(17):4850-60. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC.

Br J Haematol. 2012 Jun; 157(6):687-701. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC, Munshi NC.

Br J Haematol. 2011 Nov; 155(3):349-61. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Bae J, Tai YT, Anderson KC, Munshi NC.

Leukemia. 2011 Oct; 25(10):1610-9. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Bae J, Carrasco R, Lee AH, Prabhala R, Tai YT, Anderson KC, Munshi NC.

Conference Posters & Abstracts

Blood. 2015; 126. Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Nooka AK, Wang M, Yee AJ, Thomas SK, O’Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. (ASH Annual Meeting Abstract #4246)

Blood. 2014; 124. Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smouldering Multiple Myeloma (SMM). Wang M, Nooka AK, Yee AJ, Thomas SK, O'Donnell EK, Shah J, Weber DM, Kaufman JL, Lonial S, Avigan D, Raje N. (ASH Annual Meeting Abstract #4737)

AACR. 2014. Novel heteroclitic XBP1 peptides induce antigen-specific memory CD3+CD8+ T cells expressing critical T cell markers and transcription regulators. Bae J, Prabhala R, Carrasco R, Lee AH, Kimmelman A, Anderson KC, Munshi NC. (AACR Annual Meeting Abstract #2894)

AACR. 2014. Lenalidomide treatment enhances the anti-tumor activities of XBP1 specific cytotoxic T lymphocytes by increasing the frequency and tumor-specific response of central memory CD3+CD8+ T cells. Bae J, Prabhala R, Carrasco R, Richardson P, Dranoff G, Anderson KC, Munshi NC. (AACR Annual Meeting Abstract #638)

J Clin Oncol. 2013; 31. Novel heteroclitic XBP1 peptides evoking antigen-specific cytotoxic T lymphocytes targeting various solid tumors. Bae J, Carrasco R, Daley J, Dranoff G, Anderson KC, Munshi NC. (ASCO Annual Meeting Abstract #3067)

Blood. 2012; 120. Induction of T Cell Immunity Using a Multipeptide Cocktail Containing XBP1, CD138, CS1 Peptides in Smoldering Multiple Myeloma. Bae J, Prabhata RH, Song W, Tai YT, Anderson KC, Munshi NC. (ASH Annual Meeting Abstract #5039)

Blood. 2007; 110. Identification of CS1 Peptides for Induction of Antigen-Specific CTLs in Multiple Myeloma. Weihua Song, MD, Yu-Tzu Tai, PhD, Tetsuro Sasada, PhD, Peter Burger, BS, Mariateresa Fulciniti, PhD, Xianfeng Li, MS, Kenneth C. Anderson, MD and Nikhil C. Munshi, MD. (ASH Annual Meeting Abstract #1611)

Blood. 2005; 106. XBP-1 a Selective and Specific Target for Immunotherapy in Myeloma. Jooeun Bae, PhD, Ruben Carrasco, PhD, Kumar Sukhdeo, PhD, Pierfrancesco Tassone, MD, Paola Neri, MD, Tai Yu-Tzu, PhD, Xianfeng Li, BS, Rory Coffey, BS, Rao Prabhala, PhD, Kenneth Anderson, MD and Nikhil Munshi, MD. (ASH Annual Meeting Abstract #1594)

Blood. 2005; 106. Development of Novel CD138 Antigen-Specific Peptide Capable of Eliciting Myeloma-Specific Cytotoxic T Lymphocytes Response. Jooeun Bae, PhD, Jeff Martinson, BS, Tai Yu-Tzu, PhD, Paola Neri, MD, Pierfrancesco Tassone, MD, Xianfeng Li, BS, Rory Coffey, BS, Zhinan Xia, PhD, Rao Prabhala, PhD, Kenneth Anderson, MD and Nikhil Munshi, MD. (ASH Annual Meeting Abstract #3465)